Vir Biotechnology Will Appoint New CFO on October 5
The San Francisco biotech firm taps veteran industry executive Aziz Sawaf to lead its finance and IT divisions.
Updated on Oct. 1, 2026 in People
Live Poll
Do you trust that new executive appointments typically improve a company's long-term performance?
San Francisco-based Vir Biotechnology will welcome Aziz Sawaf as its new Executive Vice President and Chief Financial Officer starting October 5, 2026. Sawaf brings two decades of industry experience to the role as he takes charge of the company’s finance, IT, and investor relations functions.
Why it matters
The appointment marks a leadership shift for a major player in the local life sciences sector. As the company navigates ongoing development programs, Sawaf’s primary challenge will be balancing disciplined capital allocation with the advancement of therapies for patients.
The transition brings 20 years of biopharmaceutical industry experience to the role. It remains to be seen which specific development programs will be prioritized under the new financial strategy.
The players
Aziz Sawaf
The incoming Executive Vice President and Chief Financial Officer at Vir Biotechnology.
Vir Biotechnology
A San Francisco-based immunology company focused on developing treatments for infectious diseases.
Theravance Biopharma, Inc.
A biopharmaceutical company where the new CFO previously managed finance and operations strategy.
Gilead Sciences
A major research-based biopharmaceutical company where the new CFO held previous financial roles.
The details
Sawaf joins the company after serving in multiple leadership capacities at Theravance Biopharma, Inc., where he held the CFO position since 2023. Prior to his work there, he held various financial roles at Gilead Sciences. He holds degrees from the University of Arizona, the University of Southern California, and Johns Hopkins University.
Timeline
2014: Sawaf began his career at Theravance Biopharma.
2023: Sawaf started his term as CFO of Theravance Biopharma.
2025: Sawaf was named Senior Vice President of Operations Strategy.
October 5, 2026: Sawaf begins his tenure as Vir Biotechnology CFO.
Across the Bay
This appointment follows the established pattern of senior leadership migration between major regional biopharmaceutical firms. It reflects the ongoing movement of seasoned executives within the dense, interconnected life sciences cluster that defines the local economy.
Investors and local life sciences professionals should monitor upcoming investor relations disclosures for shifts in capital allocation strategy. The new leadership takes full responsibility for these operations starting October 5.
The takeaway
The arrival of a veteran CFO signals a potential pivot toward more disciplined capital management for one of the city's significant biotech employers. Keep an eye on future investor relations updates for changes in project funding priorities.
Further reading
For more on personnel shifts in the local life sciences sector, see People.
Live Poll
Do you trust that new executive appointments typically improve a company's long-term performance?
